Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 55, Issue 5, Pages 701-704Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.113.133074
Keywords
folate receptor; imaging; Tc-99m-etarfolatide; SPECT; SPECT/CT
Funding
- Endocyte Inc.
Ask authors/readers for more resources
Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non-small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. Tc-99m-etarfolatide, a Tc-99m-labeled folate conjugate, is in latephase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FR-imaging agent and how it may be used to direct FR-targeted therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available